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ealthcare administrators, policy-makers, and
practitioners must balance the needs and de-
sires of individual patients with those of society at
large, recognizing that not all needs and desires can
be met. Information comparing the expected gains
of a medical intervention against the expected costs
of that intervention versus other healthcare inter-
ventions is often difficult to interpret or compare.
The mission of the International Society for Phar-
macoeconomics and Outcomes Research (ISPOR) is
to translate pharmacoeconomics and outcomes re-
search into practice to ensure that society allocates
scarce healthcare resources wisely, fairly, and effi-
ciently. Toward this mission, ISPOR, supported by
grants from the US Department of Health and
Human Services, Agency for Healthcare Policy and
Research (grant number R13 HS09806), and the
Health Outcomes Work Group of the Pharmaceuti-
cal Research Manufacturer’s Association, convened
an Advisory Panel Meeting and Conference on
Pharmacoeconomic Issues in February 1998. This
conference provided a forum for researchers and
practitioners to communicate needs and concerns as
consensus is being developed on methodology, in-
terpretation, and use of pharmacoeconomic infor-
mation.
The objective of this interdisciplinary confer-
ence was to identify the issues in conducting phar-
macoeconomic studies, interpreting the results of
these studies, and using pharmacoeconomic infor-
mation in healthcare decisions. The specific goals
of the conference were to:
• identify key contentious methodology issues in
conducting healthcare economic evaluations
with clinical studies;
• identify key contentious methodology issues in
conducting healthcare economic evaluations us-
ing modeling studies;
• identify key contentious methodology issues in
conducting healthcare economic evaluations us-
ing databases;
• determine the education and skills needed for
conducting and/or using pharmacoeconomic
evaluations in healthcare decisions;
• identify the issues in application of economic
evaluations in healthcare intervention protocol
development, formulary decisions, and practice
guideline development and use;
• identify the issues in addressing bias, credibility,
and quality of pharmacoeconomic evaluations;
• identify the issues in communicating and report-
ing healthcare economic evaluation informa-
tion.
During this conference, 61 pharmacoeconomics
and outcomes researchers, clinical practitioners,
and healthcare decision-makers in the United States
met to develop consensus on issues relating to phar-
macoeconomic and outcomes research evaluations
and the use of these evaluations in healthcare deci-
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sions. The seven advisory panels, in closed individ-
ual panel sessions followed by open sessions includ-
ing all advisory panelists, discussed and debated the
issues.
The specific objectives of each advisory panel
and a report of each panel’s deliberations follow.
Each of the seven advisory panel papers that follow
summarizes the scientific and historical context for
the issues discussed, the numerous points of view
expressed, and the recommendations of each advi-
sory panel for future directions of research and pol-
icy in the field of pharmacoeconomics. These pa-
pers are working documents presented as a basis
for standardization of the science of outcomes re-
search and healthcare economics, the development
of generally accepted pharmacoeconomic policies,
and an agenda for future research activities. A sum-
mary of the results of the advisory panel delibera-
tions follows.
 
Panel 1: Methodological Issues
in Pharmacoeconomic
Evaluations—Clinical Studies
 
Pharmacoeconomic methods used to assess cost
alone or other measures of value often fall short of
regulatory standards. Conversely, study methods
used to demonstrate drug efficacy, such as random-
ized clinical studies, are insufficient for addressing
the question of value in applied settings. To over-
come the limitations of using clinical studies data
for health economic evaluations, researchers, deci-
sion-makers, policy-makers, and consumers should
be well versed in the appropriate use of clinical
studies.
The four key issues identified are:
1. Under what circumstances should randomized
controlled trials (RCTs) be the primary ap-
proach for assessing questions of value?
2. How can RCTs be modified to improve their
usefulness to inform economic decision-making?
3. Under what circumstances can observational
studies be used to assess questions of value?
4. How can observational studies be modified to
improve their usefulness to inform economic
decision-making?
The panel’s recommendations are:
• Develop new methods to account for protocol-
related costs (particularly in studies where these
costs cannot be equated across study groups).
• Develop consensus on the definition of usual
care. With the recommendation that trials should
adopt more naturalistic designs, it is anticipated
that the use of “usual care” as a comparator will
continue to increase.
• Explore methods to supplement intent-to-treat
analyses in usual care trials to address research
questions important to decision-makers that
may require alternate or additional analysis.
• Address problems of pooling economic data
from multiple study sites. This problem is ex-
acerbated in international studies where data
are collected across countries.
• Improve statistical methods for adjusting for
selection bias, which is a major drawback of
observational studies.
• Use better methods for estimating variance
around resource utilization and cost.
• Conduct systematic comparisons of RCTs and
observational studies of the same interventions.
• Explore approaches from other disciplines (e.g.,
psychology, sociology, marketing research) to
enhance current methods, particularly in the ar-
eas of data collection, instrumentation, and an-
alytic techniques.
• Measure resource utilization in large simple tri-
als. Resources currently dedicated to marketing
studies could be reallocated for the identifica-
tion and collection of relevant economic data.
• Create better methods of measuring direct
medical costs that are not routinely captured
(e.g., nursing time, telephone care).
• Create better methods of measuring relevant
indirect costs (e.g., caregiver, lost productiv-
ity). There needs to be a greater appreciation
of these cost drivers, and simple, easy methods
to measure and document them.
• Encourage inclusion of standardized outcome
measures in the evolving electronic medical
record.
 
Panel 2: Methodological Issues in
Conducting Pharmacoeconomic
Evaluations—Modeling Studies
 
The primary purpose of modeling is to inform the
decision-making process. One considerable benefit
of model formalization is that the uncertainties and
assumptions in this process are made explicit and
transparent. Currently two major obstacles con-
fronting modeling methodology are: (1) How do
we optimize the production of useful information
for health economic decision-makers? (2) How do
we encourage its acceptance and use?
Seven key areas of controversy in modeling
methodology are:
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1. standardization;
2. making choices;
3. methodological development;
4. extending clinical studies and data issues;
5. effectiveness measures;
6. model validation;
7. peer review.
The panel’s recommendations are:
• Work towards general acceptance that model-
ing of both costs and effectiveness is a valid and
often essential method to inform healthcare de-
cision-making.
• Assemble a consensus of opinion on standard-
ized practices and policies.
• Prepare and disseminate a reference text of
these practices once standardization has been
achieved.
• Permit pharmacoeconomic claims based on
these generally accepted modeling approaches
by regulatory agencies; always be transparent
and include appropriate disclaimers.
• Initiate and assemble a balanced international
panel of thought-leaders and end-users in the
field of modeling to develop a package of gen-
erally accepted modeling practices.
• Encourage all stakeholders (professional socie-
ties, manufacturing associations, journals, gov-
ernment agencies, regulatory agencies, payers,
and healthcare providers) to accept these stan-
dards and to endorse their use once these prac-
tices have been documented.
 
Panel 3: Methodological Issues in 
Conducting Pharmacoeconomic 
Evaluations—Retrospective and 
Claims Database Studies
 
Healthcare decision-makers require rapid access
to information. Often the evidence to assist deci-
sion-makers in drawing conclusions has not been
available. Both RCTs and retrospective methods
using existing databases provide such informa-
tion, and they typically answer different questions.
Most RCTs are designed to measure efficacy, not
effectiveness. “Real-world” data can be provided
by database studies.
Eight key issues are identified:
1. What research questions can be answered by
retrospective analyses?
2. What data sources are available to answer these
questions?
3. How is cost-effectiveness measured using auto-
mated databases?
4. How can data quality within a database be
evaluated?
5. What types of statistical methods can be uti-
lized to control for treatment effects?
6. What potential types of bias exist in retrospec-
tive database analyses?
7. What alternative methods for assessing selec-
tion bias are available?
8. How can transparency be ensured in retrospec-
tive database analyses?
The panel’s recommendations are:
• Begin retrospective database analysis studies with
a clear question and design, based on guidelines
for good epidemiological practices.
• Ensure privacy of individuals at all times in
retrospective database analyses.
• Use techniques that exist to address shortcom-
ings of retrospective data sets.
• Subject multivariate models to extensive speci-
fication testing.
• Examine age- or gender-adjusted utilization rates
and annual per capita expense by payer, health
plan, geographic region, and country.
• Augment administrative databases, frequently
used for retrospective pharmacoeconomic stud-
ies, to include more clinical information.
• Establish standard measures to deal with all
areas of potential bias.
 
Panel 4: Education and Skills Needed to 
Conduct, Interpret, and Use Economic 
Evaluations in Healthcare
 
Like other disciplines, to expand and grow as a ma-
ture area of research and application, the field of
health economics requires experts and skilled pro-
fessionals. Unlike many other scientific fields, there
is no single background or training to prepare the
researcher or the user of health economic informa-
tion, who currently come from a diversity of educa-
tional and experiential backgrounds.
The key issues related to education and skills in
the field of health economics are as follows:
1. The structuring of multidisciplinary programs
needs to be defined for people coming from a
variety of backgrounds.
2. Training must include “real-world” applications.
3. It is unlikely that an “ideal program” can be
created within one institution or group without
collaboration with others.
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4. The usefulness of defined “minimal competen-
cies” in the field has to be determined. Minimal
competencies will differ for current and future
practitioners, and by depth of involvement.
5. Questions need to be answered pertaining to
who should be trained, how training should be
performed, and what level of training is required.
6. The necessity for “credentialing” needs to be
assessed.
7. There is a need to improve the way information
concerning training opportunities is dissemi-
nated.
The panel’s recommendations are:
• Develop three levels of expertise: awareness,
application, and conceptualization.
• Develop access to detailed information about
available educational programs in the field of
health economics.
• Utilize relevant educational resources outside
of health economics to enhance the educa-
tional infrastructure.
• Accommodate multidisciplinary participants
through the availability of prerequisite train-
ings and flexible core course offerings for de-
gree programs.
• Balance didactic and experiential education.
• Develop a credentialing process to establish
standards for the field.
• Standardize training and certification through a
three-step process: (1) develop guidelines for
postprofessional degree training; (2) accredit
pharmacoeconomic residencies and fellowships;
and (3) establish collaborations with other or-
ganizations to expand accreditation to other rel-
evant residencies.
 
Panel 5: Application of Healthcare 
Intervention Economic Evaluations in 
Healthcare Decision-Making
 
Information about the impact of new therapies on
costs within a healthcare system should be essential
for making better healthcare decisions. However,
the relevance of health economic information to
decision-makers has not been demonstrated. There
is little user-friendliness in health economic data.
There is a lack of consistency of approach and for-
mat that would facilitate comparison, and much of
the information presented lacks the transparency
necessary for the user to determine the appropri-
ateness of methods or the soundness of assump-
tions. A fundamental disconnect exists between (1)
the way decisions are made by healthcare decision-
makers, (2) the type of information presented to
healthcare decision-makers, and (3) the type of in-
formation produced by health economic and out-
comes researchers.
There are 11 key issues:
1. Evaluative criteria are often weighed differ-
ently by potential users of health economic re-
search data for decision-making purposes, such
as formulary committees, providers, health
plan managers, patients, and employers.
2. Language and definitional barriers hinder ef-
fective communication between potential us-
ers and producers of the information.
3. There is little of the direct treatment compari-
son done that would be of greatest interest to
users.
4. Insufficient dialogue exists between potential
users and producers of information on rele-
vancy and availability of information gener-
ated by health economic research.
5. Potential users of health economic research
data may be hesitant to include health eco-
nomic information in their decision-making
process because it is unfamiliar.
6. There may be conflict between studies designed
to provide health economic and outcomes in-
formation that meets user’s needs and those of
clinical design, causing regulatory and liability
concerns.
7. Some sources of research funding may present
a barrier to the credibility and application of
study results.
8. A conflict may exist between recommenda-
tions based on population data and the care
of individual patients.
9. When health economic research data are used
in the decision-making process, there is no
recognized approach for measuring the qual-
ity of the decision or the net result.
10. There are few skilled opinion leaders or other
resources from which potential users can seek
advice and assistance.
11. Decision-maker organizations segregate budget-
ary decisions for pharmaceuticals from those re-
lated to other medical technologies and services.
The panel’s recommendations are:
• A central organization should coordinate the de-
velopment of application of healthcare interven-
tion economic evaluations in healthcare decision-
making.
• Create focus groups to provide a forum for dia-
logue between potential users, producers, and
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regulators of information. Researchers and sup-
pliers of health economic data must actively en-
gage with decision-makers to determine key
health economic evaluation criteria for decision-
making purposes and to formulate ways to sup-
ply information consistently.
• Determine a set of variables that researchers
can supply. Decisions are seldom made using a
single variable.
• Develop a set of simple criteria for evaluation of
these studies. They should be agreed upon by
consensus of all parties involved and designed
to recognize different types of perspectives and
research design so that specified research ques-
tions and business needs are met.
• Seek to bolster the objectivity, reliability, and
credibility of the health economic studies through
various mechanisms, including working with
sponsors, researchers, and journal editors, to
adopt protocols that will establish the indepen-
dence of research and statements for the dis-
closure of funding sources.
• Offer training for decision-makers in using health
economic research information. A consortium of
managed care and other purchasing organiza-
tions, academic researchers, and one or more
health economic research organizations should
be formed to execute this recommendation.
• Develop a standard reporting format to allow
flexible weighting of factors based on individ-
ual decision-making preferences. The presenta-
tion of the results of health economic analyses
should show the various components of effec-
tiveness measures, service utilization measures,
and costs.
• Form a committee to produce a standard for-
mat for Data Element Shells (DES). ISPOR, in
collaboration with potential users and produc-
ers of information, could be responsible for cre-
ation and updating of a DES form. The ISPOR
committee would decide on the level of specific-
ity of the DES, perhaps either a general format
for all drugs or a specific format for individual
drug classes.
• Support an information clearinghouse of avail-
able thought-leaders and experts in the field.
This could include development and mainte-
nance of an Internet Web site with links to ex-
pert’s homepages and email addresses. ISPOR
as an organization brings together many of the
researchers qualified to evaluate health eco-
nomic research and interpret findings.
• Develop rosters of persons qualified to review
studies, similar to editorial boards for journals,
where the reviewers would agree to participate
in reviewing documents or addressing queries
to promote a better understanding of the field
of healthcare economics.
 
Panel 6: Addressing Questions of Bias, 
Credibility, and Quality in Health 
Economic Evaluations
 
Multiple published studies have criticized the rigor,
relevance, objectivity, methods, and reports pro-
duced within the health economic research domain.
Consequently, health economic research findings
are not used as extensively as they could be, and ra-
tional decision processes about the efficient use of
healthcare resources may not be fully informed. Ul-
timately, care for patients and populations may be
adversely affected. In this context, there is a need
for continued improvement in the quality of eco-
nomic research conducted.
There are three key issues:
1. Quality: Are the best methods being used?
2. Bias: Whether it is real or perceived, how do we
deal with it?
3. Credibility: Do we have a problem with believ-
ability or with relevance?
The panel’s recommendations are:
• Design and conduct studies using the best avail-
able practices consistent with the study objec-
tives.
• Disclose all financial relationships.
• Authorship should conform to generally recog-
nized practices among the peer research com-
munity.
• Research data should be transparent, including
full disclosure and sufficient information to al-
low replication. Given this, it should be judged
solely on the merits of its content.
• Develop a code of ethics for health economic
researchers.
• Develop study methodology practice standards.
• Convene a conference similar to this conference
in 2 years to evaluate progress and recommend
next steps.
 
Panel 7: Communication and Reporting 
Health Economic Information
 
Users of health economic information represent
many different perspectives with various levels of
expertise and information needs. To obtain most
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value from the resources invested in health eco-
nomic research, how do we optimize the effective-
ness of communication of health economic infor-
mation?
There are three key issues:
1. Relevance: Is it needed?
2. Usefulness: Will the intended audience be able
to make use of it?
3. Credibility: Is it believable?
The panel’s recommendations are:
• Identify the needs of users of health economic
information. A survey of all users of health
economic information will provide a basis for
standardization of communications.
• Establish standard communication formats
based on predetermined relevance, information,
and credibility needs of users and on standard
health economic performance standards that
should be under development elsewhere. These
should eventually include uniform presentation,
standard terminology, and adequate disclosure,
and should have a basis in previously published
guidelines.
• Adopt reporting guidances (RGs) and apply
these to all publicly presented communications,
as standardized formats are established.
• Evaluate the use of RGs and the quality of re-
porting on a biannual basis.
• Establish a principle of publicly accessible re-
ports that adhere to ISPOR RGs. This would
allow access to research reports not directly con-
trolled by the researcher or the research organi-
zation. Once a report has been “filed” for pub-
lic accessibility, all subsequent communications
could refer to that report.
• Institute an enhanced mode of peer review for
all forms of health economic communications.
This type of review would assure that there
was compliance with ISPOR RGs, as well as
fair, full, and adequate disclosure, allow for re-
view of the underlying data and any model
used, and confirm that all other ISPOR stan-
dards for the conduct of health economic stud-
ies have been met.
 
Expected Outcomes of the Conference
 
The expected products of this conference are:
1. Publication: These papers are to be published in
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, the Journal of the International
Society for Pharmacoeconomics and Outcomes
Research.
2. Follow-up activities: Conferences are planned
based on the recommendations given in this re-
port.
3. ISPOR policy statements: Specific policies of the
International Society for Pharmacoeconomics
and Outcomes Research will be developed from
these recommendations. ISPOR, in cooperation
with other scientific, practitioner, and institu-
tional organizations, will work to implement
these policies. These organizations include the
Health Outcomes Work Group of the Pharma-
ceutical Research Manufacturers of America and
the Pharmaceutical Research Standards Commit-
tee of the American Managed Care Pharmacy
Association.
4. Agenda for future research activities. The rec-
ommendations included in these reports are pro-
posed as the agenda for future research activities
by the Agency for Health Care Policy and Re-
search.
 
In addition to the advisory panel co-chairs and panelists, the
following pharmacoeconomic researchers participated in
the meeting: Daniel Mullins, PhD, University of Maryland,
Baltimore, MD, Tom Einarson, PhD, University of Tor-
onto, Canada, William McGhan, PharmD, PhD, University
of the Sciences in Philadelphia, Philadelphia, PA, James
Smeeding, RPh, MBA, University of Texas, Austin, TX,
Hugh Tilson, MD, DrPH, Glaxo Welcome, Research Trian-
gle Park, NC, and Yen-Pin Chiang, PhD (observer), Agency
for Health Care Policy and Research, Rockville, MD.
This conference and publication was supported by a
grant from the United States Department of Health and
Human Services, Agency for Health Care Policy and Re-
search, and the Health Outcomes Work Group of the Phar-
maceutical Research and Manufacturers of America. This
project was supported by grant number R13 HS09806
from the Agency for Health Care Policy and Research.
The views expressed herein are those of the panelists
and do not necessarily represent the position of the organi-
zations for which they work.
